Andrew Capen

1.9k total citations
19 papers, 724 citations indexed

About

Andrew Capen is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Andrew Capen has authored 19 papers receiving a total of 724 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 7 papers in Oncology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Andrew Capen's work include Cancer Mechanisms and Therapy (4 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Lung Cancer Research Studies (3 papers). Andrew Capen is often cited by papers focused on Cancer Mechanisms and Therapy (4 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Lung Cancer Research Studies (3 papers). Andrew Capen collaborates with scholars based in United States, Spain and United Kingdom. Andrew Capen's co-authors include Sandaruwan Geeganage, Bruce W. Konicek, Lillian Sams, Jeremy R. Graff, Philip W. Iversen, Thomas J. Brown, Luna Musib, Karen Huss, Rebecca L. Lynch and Ann M. McNulty and has published in prestigious journals such as PLoS ONE, Cancer Research and Clinical Cancer Research.

In The Last Decade

Andrew Capen

18 papers receiving 711 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrew Capen United States	9	511	212	121	103	99	19	724
Michel Maira Switzerland	8	629 1.2×	269 1.3×	124 1.0×	124 1.2×	180 1.8×	12	837
Rebecca L. Lynch United States	4	452 0.9×	143 0.7×	108 0.9×	89 0.9×	98 1.0×	4	615
Jiahuai Tan United States	8	548 1.1×	165 0.8×	67 0.6×	52 0.5×	48 0.5×	16	687
Rosalin Mishra United States	11	421 0.8×	345 1.6×	58 0.5×	56 0.5×	139 1.4×	20	724
Tiffany A. LaFortune United States	10	592 1.2×	273 1.3×	185 1.5×	98 1.0×	103 1.0×	13	902
Shengyan Xiang United States	16	765 1.5×	273 1.3×	48 0.4×	61 0.6×	69 0.7×	25	919
Jennifer R. Stephens United States	9	303 0.6×	175 0.8×	82 0.7×	100 1.0×	94 0.9×	23	486
Scott Ackler United States	8	472 0.9×	233 1.1×	76 0.6×	94 0.9×	45 0.5×	10	625
Samar Alanazi United States	8	347 0.7×	271 1.3×	48 0.4×	46 0.4×	102 1.0×	13	575
Donald P. Lesslie United States	8	397 0.8×	353 1.7×	58 0.5×	71 0.7×	87 0.9×	11	687

Countries citing papers authored by Andrew Capen

Since Specialization

Citations

This map shows the geographic impact of Andrew Capen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Capen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Capen more than expected).

Fields of papers citing papers by Andrew Capen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Capen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Capen. The network helps show where Andrew Capen may publish in the future.

Co-authorship network of co-authors of Andrew Capen

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Capen. A scholar is included among the top collaborators of Andrew Capen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Capen. Andrew Capen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Gong, Xueqian, Hong Gao, Mark H. Bender, et al.. (2024). Abstract 3316: LY3962673, an oral, highly potent, mutant-selective, and non-covalent KRAS G12D inhibitor demonstrates robust anti-tumor activity in KRAS G12D models. Cancer Research. 84(6_Supplement). 3316–3316. 7 indexed citations

Mur, Cecilia, W K Shen, Carlos Marugán, et al.. (2023). 41P Preclinical characterization of imlunestrant, an oral brain-penetrant selective estrogen receptor degrader with activity in a brain metastasis (BM) model. ESMO Open. 8(1). 101265–101265. 1 indexed citations

Li, Binghui, Trent R. Stewart, Tao Wang, et al.. (2023). Abstract B115: Preclinical characterization of LY3962673, an orally bioavailable, highly potent, and selective KRAS G12D inhibitor. Molecular Cancer Therapeutics. 22(12_Supplement). B115–B115.

Hong, David S., Kathleen N. Moore, Johanna C. Bendell, et al.. (2021). Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor. Clinical Cancer Research. 27(7). 1864–1874. 37 indexed citations

Wu, Wenjuan, Gregory P. Donoho, Philip W. Iversen, et al.. (2019). Abstract 3508: Combination of the Chk1 inhibitor (prexasertib) with a PI3K/mTOR inhibitor (LY3023414) induces synergistic anti-tumor activity in triple negative breast cancer (TNBC) models. Cancer Research. 79(13_Supplement). 3508–3508. 3 indexed citations

Novosiadly, Ruslan D., David Schaer, Nelusha Amaladas, et al.. (2018). Abstract 4549: Pemetrexed enhances anti-tumor efficacy of PD1 pathway blockade by promoting intra tumor immune response via immunogenic tumor cell death and T cell intrinsic mechanisms. Cancer Research. 78(13_Supplement). 4549–4549. 8 indexed citations

Wu, Wenjuan, Constance King, Gregory P. Donoho, et al.. (2018). Abstract 336: Anti-tumor activity of the Chk1 inhibitor prexasertib (LY2606368) as a single agent in triple negative breast cancer models. Cancer Research. 78(13_Supplement). 336–336. 4 indexed citations

Konicek, Bruce W., Andrew Capen, Kelly M. Credille, et al.. (2018). Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors. Oncotarget. 9(17). 13796–13806. 38 indexed citations

Dempsey, Jack, Lysiane Huber, Amélie Forest, et al.. (2017). Abstract 583: The CDK4/6 inhibitor abemaciclib induces synergistic immune activation and antitumor efficacy in combination with PD-L1 blockade. Cancer Research. 77(13_Supplement). 583–583. 2 indexed citations

10.

Novosiadly, Ruslan D., David Schaer, Zhen Lu, et al.. (2017). P3.07-006 Pemetrexed Exerts Intratumor Immunomodulatory Effects and Enhances Efficacy of Immune Checkpoint Blockade in MC38 Syngeneic Mouse Tumor Model. Journal of Thoracic Oncology. 12(11). S2300–S2300. 3 indexed citations

11.

Konicek, Bruce W., Andrew Capen, John Calley, et al.. (2016). Abstract 2647: Merestinib (LY2801653), targeting several oncokinases including NTRK1/2/3, shows potent anti-tumor effect in colorectal cell line- and patient-derived xenograft (PDX) model bearing TPM3-NTRK1 fusion. Cancer Research. 76(14_Supplement). 2647–2647. 1 indexed citations

12.

Smith, Rosamund C., Martin S. Cramer, Pamela J. Mitchell, et al.. (2015). Myostatin Neutralization Results in Preservation of Muscle Mass and Strength in Preclinical Models of Tumor-Induced Muscle Wasting. Molecular Cancer Therapeutics. 14(7). 1661–1670. 30 indexed citations

13.

Atkinson, Jennifer M., Kenneth B. Rank, Yi Arial Zeng, et al.. (2015). Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma – Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3. PLoS ONE. 10(4). e0125028–e0125028. 91 indexed citations

14.

Tolcher, Anthony W., Jonathan H. Goldman, Amita Patnaik, et al.. (2014). A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours. European Journal of Cancer. 50(5). 867–875. 45 indexed citations

15.

Bender, Mark H., Hong Gao, Andrew Capen, et al.. (2013). Abstract 1131: Novel inhibitor of Notch signaling for the treatment of cancer.. Cancer Research. 73(8_Supplement). 1131–1131. 13 indexed citations

16.

Meier, Timothy I., Mark Uhlik, Sudhakar Chintharlapalli, et al.. (2011). Tasisulam Sodium, an Antitumor Agent That Inhibits Mitotic Progression and Induces Vascular Normalization. Molecular Cancer Therapeutics. 10(11). 2168–2178. 31 indexed citations

17.

Bender, Mark H., Philip A. Hipskind, Andrew Capen, et al.. (2011). Abstract 2819: Identification and characterization of a novel smoothened antagonist for the treatment of cancer with deregulated hedgehog signaling. Cancer Research. 71(8_Supplement). 2819–2819. 43 indexed citations

18.

Graff, Jeremy R., Stephen H. Parsons, Jana A. Lewis, et al.. (2006). 580 POSTER Enzastaurin (LY317615.HCl) suppresses signaling through the PKC and AKT pathways, inducing apoptosis, suppressig tumor-induced angiogenesis and reducing growth of human cancer xenografts. European Journal of Cancer Supplements. 4(12). 176–176. 5 indexed citations

19.

Graff, Jeremy R., Ann M. McNulty, Bruce W. Konicek, et al.. (2005). The Protein Kinase Cβ–Selective Inhibitor, Enzastaurin (LY317615.HCl), Suppresses Signaling through the AKT Pathway, Induces Apoptosis, and Suppresses Growth of Human Colon Cancer and Glioblastoma Xenografts. Cancer Research. 65(16). 7462–7469. 362 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact